Cargando…

Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas

Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braunstein, Zachary, Ruiz, Miguel, Hanel, Walter, Shindiapina, Polina, Reneau, John C., Brammer, Jonathan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225101/ https://www.ncbi.nlm.nih.gov/pubmed/35743749 http://dx.doi.org/10.3390/jpm12060964

Ejemplares similares

Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
por: Reneau, John C., et al.
Publicado: (2022)

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
por: Hanel, Walter, et al.
Publicado: (2023)

Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
por: Pongas, Georgios, et al.
Publicado: (2021)

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents
por: Faisal, Muhammad Salman, et al.
Publicado: (2023)

Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma
por: Stuver, Robert, et al.
Publicado: (2023)

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
por: Hood, Katelyn, et al.
Publicado: (2016)

Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
por: Rodd, Annabelle L., et al.
Publicado: (2012)

Treatment approaches in relapsed or refractory peripheral T-cell lymphomas
por: Foster, Cheryl, et al.
Publicado: (2020)

P1071: COMBINATION OF PD-1 INHIBITION WITH IMMUNOMODULATORY DRUG TREATMENT IN HODGKIN AND LARGE B-CELL LYMPHOMA: RESULTS FROM A PHASE I/II STUDY
por: Bond, David, et al.
Publicado: (2023)

Cyclophosphamide induces durable molecular and clinical responses in patients with relapsed T-LGL leukemia
por: Braunstein, Zachary, et al.
Publicado: (2022)

Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
por: Bodiford, Andrew, et al.
Publicado: (2014)

Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
por: Braunstein, Zachary, et al.
Publicado: (2022)

Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy
por: Annunzio, Kaitlin, et al.
Publicado: (2022)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphoma
por: Foss, Francine, et al.
Publicado: (2016)

Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review
por: Makita, Shinichi, et al.
Publicado: (2018)

P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY
por: Mehta-Shah, Neha, et al.
Publicado: (2023)

Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes
por: Al-Juhaishi, Taha, et al.
Publicado: (2022)

Management of relapsed-refractory diffuse large B cell lymphoma
por: Raut, Lalit S., et al.
Publicado: (2014)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
por: Denlinger, Nathan M, et al.
Publicado: (2018)

Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
por: Quadri, Iman, et al.
Publicado: (2023)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
por: Bennani, N Nora, et al.
Publicado: (2022)

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia
por: Ma, Jiale, et al.
Publicado: (2021)

P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS
por: Zinzani, P. L., et al.
Publicado: (2022)

Kinase Inhibition in Relapsed/Refractory Leukemia and Lymphoma Settings: Recent Prospects into Clinical Investigations
por: Machado, Caio Bezerra, et al.
Publicado: (2021)

Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
por: Shi, Yuankai, et al.
Publicado: (2017)

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study
por: Reboursiere, Emilie, et al.
Publicado: (2016)

Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study
por: Kim, Won-Seog, et al.
Publicado: (2023)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017)

The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021)

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
por: Coiffier, Bertrand, et al.
Publicado: (2014)

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
por: Hong, Xiaonan, et al.
Publicado: (2019)

Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma
por: Kawai, Hidetsugu, et al.
Publicado: (2021)

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
por: Rai, Shinya, et al.
Publicado: (2022)

Recent advances in the management of Hodgkin lymphoma
por: Villasboas, Jose C., et al.
Publicado: (2016)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_lj6ennakfudm1v7lc9ll8l48kg